# Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation

Source: https://onco.cc/trials/nct05288205/  
OnCo record `nct05288205` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Glecirasib, Sitneprotafib in non-small-cell lung cancer and small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.

## Summary

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation is a phase 1/2 interventional study registered as NCT05288205 by Allist Pharmaceuticals, Inc., with 240 participants planned, started 2022-04-14 and due to reach its primary completion in 2027-03. Interventions recorded: JAB-21822, JAB-3312. Conditions listed: KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05288205
- Phase: 1/2
- Setting: A Phase 1/2a Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of JAB-21822 in Combination With JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
- Sponsor: Allist Pharmaceuticals, Inc.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT05288205: https://clinicaltrials.gov/study/NCT05288205

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Glecirasib](https://onco.cc/drugs/glecirasib/), [Sitneprotafib](https://onco.cc/drugs/sitneprotafib/)
- companies: [Shanghai Allist Pharmaceuticals](https://onco.cc/companies/allist/)

---
JSON: https://onco.cc/api/v1/entities/nct05288205.json